Arkansas health care company Rejuvenix Technologies has landed a National Cancer Institute contract worth more than $300,000 to develop new technologies to delivery chemotherapy.
The company received a $383,213 National Cancer Institute Small Business Innovation Research Phase I contract. The project will be to develop encapsulated radiation-triggered liposomes that can be used to provide a “safer, controlled delivery of chemotherapy.”
Rejuvenix also received $50,000 in matching funds from the Arkansas Economic Development Commission. The Arkansas Small Businesses and Technology Development Center (ASBTDC) provided assistance with the SBIR award process.
For this project, Rejuvenix is teaming up with the University of Arkansas for Medical Sciences.
“Our patented technology utilizes localized ionizing radiation to trigger the release of chemotherapeutic agents that are contained within radio-sensitive liposomes. The technology greatly minimizes the toxic exposure to vital organs while potentially enhances overall efficacy of combined radiation and chemotherapy standards of care,” Rejuvenix CEO Joshua Philips said in a statement.
The Rejuvenix team also includes chief scientific officer Dr. Amanda Stolarz, chief regulatory officer Dr. Jay Gandy, and principal investigator and vice president for research and development Robert Griffin, Ph.D.
“Our platform will eliminate or significantly reduce the impact of chemotherapy side effects to other vital organs. It also presents the opportunity for chemotherapy to damage or kill tumor cells, which we expect will create a more than additive total amount of tumor cell killing while reducing the typical systemic effects of traditional chemotherapy, which include a weakened immune system and potential for life threatening infections among other damage to normal tissues,” Griffin said.